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Abstract
Background: Dietary intake of vitamin K has been reported to reduce coronary artery calcification (CAC) and
cardiovascular events. However, it is unknown whether supplemental menaquinone (MK)-4 can reduce CAC or
arterial stiffness. To study the effect of MK-4 supplementation on CAC and brachial ankle pulse wave velocity
(baPWV).
Methods: This study is a single arm design to take 45 mg/day MK-4 daily as a therapeutic drug for 1 year. Primary
endpoint was CAC score determined using 64-slice multislice CT (Siemens), and the secondary endpoint was
baPWV measured before and 1 year after MK-4 therapy.
Results: A total of 26 patients were enrolled. The average age was 69 ± 8 years and 65 % were female. Plasma
levels of phylloquinone (PK), MK-7, and MK4 were 1.94 ± 1.38 ng/ml, 14.2 ± 11.9 ng/ml and 0.4 ± 2.0 ng/ml,
respectively, suggesting that MK-7 was the dominant vitamin K in the studied population. Baseline CAC and baPWV
were 513 ± 773 and 1834 ± 289 cm/s, respectively. At 1 year following MK-4 supplementation, the values were
588 ± 872 (+14 %) and 1821 ± 378 cm/s (−0.7 %), respectively. In patients with high PIVKA-2, −18 % annual
reduction of baPWV was observed.
Conclusion: Despite high dose MK-4 supplementation, CAC increased +14 % annually, but baPWV did not
change (−0.7 %). The benefits of MK-4 supplementation were only observed in patients with vitamin K
insufficiencies correlated with high PIVKA-2 baseline levels, reducing baPWV but not CAC.
Trial registration: This study was registered as UMIN 000002760
Keywords: Vitamin K, Coronary artery calcification, Pulse wave velocity
Introduction
Coronary artery calcification (CAC) forms in the patho-
genesis of atherosclerosis [1] and is associated with a
higher risk of cardiovascular events [2, 3]. Annual
changes of CAC-scores are considered to be relevant
with severity of atherosclerosis [1, 2]. The vitamin K
dependent Matrix Gla protein (MGP) plays a role as an
inhibitor of soft tissue calcification [1, 4–6]. Patients
with therapeutic vitamin K antagonist tended to have
more valvular, vascular and coronary calcification [7, 8].
Observational studies in humans showed an inverse
relationship between menaquinone (MK) intake and
CAC in healthy elderly [9, 10]. Phylloquinone (PK) sup-
plementation was shown to retard the progression of
CAC and had a beneficial effect on vascular stiffness in
healthy adults with coronary artery calcification after
3 years of follow-up [11–13]. A randomized, double-
blind, placebo-controlled trial to investigate the effect of
menaquinone-7 (MK-7) supplementation on MGP spe-
cies showed a dose-dependent decrease of dephospho-
uncarboxylated MGP (dp-ucMGP) concentrations [14].
Furthermore, MK-7 improves arterial stiffness and elas-
tic properties of the carotid artery [15]. These data may
suggest that vitamin K administration may have benefi-
cial effects on the vasculature. Supplementation studies
using MK-4 has been few. This pilot study analyzed the
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impact of MK-4 supplementation on CAC and arterial
stiffness.
Methods
Patient selection and study protocol
Patients with at least one coronary risk factor (coronary
risk factors were defined as hypertension, diabetes melli-
tus, hypercholesterolemia, smoking, and family history
of coronary artery disease) were enrolled. Exclusion cri-
teria were patients with implantation of coronary stent
or pacemaker, or inability to obtain correct coronary ar-
tery calcification (CAC) score or brachial ankle pulse
wave velocity (baPWV) data. Written informed consent
was obtained from each participant. The Institutional
Review Board approved the study and all patients gave
written informed consent. Medical histories, including
prior myocardial infarction, prior percutaneous coronary
intervention, prior coronary artery bypass graft surgery,
prior heart failure, prior stroke, and hemodialysis, were
obtained for each patient. The correlation between cor-
onary artery calcification score, aortic stiffness and each
factor was studied.
Menqauinone-4 treatment
A tablet containing 15 mg of MK-4 (Eizai, Tokyo) was
prescribed three times a day. This drug is approved for
osteoporosis and is commercially available in Japan. If
any side effects of the MK-4 treatment occurred, it was
to be reported to the study center. In the case of newly
onset atrial fibrillation, MK-4 could be stopped if vita-
min K antagonist was indicated to prevent stroke.
Cardiac multi-slice computed tomography data
acquisition and analysis
In all patients, a prospective non-enhanced coronary cal-
cium scan was performed with a 64-slice MSCT scanner
(Siemens, Munich, Germany). For quantitative assess-
ment of coronary artery calcification, the Agatston score
[16] was calculated, using a 3 mm CT slice thickness
and a detection threshold of 130 Hounsfield units (HU)
involving ≧ 1 mm2 area/lesion (3 pixels). Total CAC
score was determined by summing individual lesion
scores from each of four anatomic sites (left main trunk,
left anterior descending artery, left circumflex artery,
and right coronary artery) [17]. The measurement was
performed using syngo calcium scoring software sup-
plied by Siemens. The inter-observer and intra-observer
errors were reported as coefficient of variation of 2.1
and 1.3 [18]. CT was performed before starting MK-4
and 1 year after MK-4 treatment.
Measurement
Plasma was obtained from the patients in the morning
after overnight fasting and stored at – 30 °C. Vitamin K
(PK, MK-4, and MK-7) was determined by the high-per-
formance liquid chromatography-tandem mass spectrom-
etry (LC-APCIMS/MS) method [19]. Total circulating
uncarboxylated matrix gla protein (t-ucMGP) measure-
ments were done by Dr. Vermeer’s group. Intact parathy-
roid hormone, osteocalcin (OC), ucOC, NTX and bone
type alkaline phosphatase (BAP) and high sensitive C-
reactive protein were measured by SRL Inc (Tokyo, Japan).
Bone density was measured at lumbar vertebra using
DSC-900FX (Hitachi-Aloka Medical, Tokyo). The ankle
brachial index (ABI) and baPWV were measured using
BP-203 RPE (Omron-Colin, Kyoto).
Endpoints
The primary endpoint of this study was CAC score dif-
ference between baseline and 1 year after MK-4 treat-
ment. The secondary endpoint was baPWV difference.
Other plasma data and clinical data were obtained at
baseline.
Table 1 Patient background
Number 26
Female gender 65 %
Age 69 ± 8
Height 157 ± 9
Weight 57 ± 11
Body mass index 22.8 ± 3.2
Current smoker 27 %
Diabetes mellitus 15 %
Hypertension 73 %
Dyslipidemia 81 %
History of myocardial infarction 15 %
Prior coronary artery bypass surgery 4 %
History of stroke 4 %
Ankle brachial index 1.11 ± 0.39
ba-pWV (cm/s) 1834 ± 289
Bone matrix 1.053 ± 0.251
% Bone matrix 117 ± 20 %




ACEI or ARB 54 %
Calcium antagonist 58 %
beta blocker 19 %
Insulin 8 %
ba-pWV brachial ankle pulse wave velocity
ACEI angiotensin converting enzyme inhibitor
ARB angiotensin receptor blocker
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Statistics
We present continuous variables as mean ± standard devi-
ation in normal distribution or median and interquartile
range. Categorical variables were presented as absolute
numbers and percentages. Statistical analysis was
performed with SAS version 9.2, (SAS Institute, Inc., Cary
NC). This study was registered as UMIN 000002760.
Results
A total of 26 patients were enrolled. Baseline characteris-
tics are shown in Table 1. The average age was 69 ± 8 years
and 65 % were female. Diabetes was 15 % and the ankle
brachial index was 1.11 ± 0.39. Baseline baPWV was
1834 ± 289 and the CAC score was 513 ± 773 (median
264 [48–484]).
Baseline blood test data are shown in Table 2. Uncar-
boxylated osteocalcin (ucOC) was 3.7 ± 2.5 ng/ml and
PIVKA2 was 19 ± 7 mAU/mL. Plasma levels of PK, MK-7,
and MK4 were 1.94 ± 1.38 ng/ml, 14.2 ± 11.9 ng/ml and
0.4 ± 2.0 ng/ml, respectively. This suggests that MK-7 was
the dominant vitamin K in the studied population.
CAC and baPWV data before and after MK-4 treat-
ment are shown in Table 3. CAC significantly increased
despite the MK-4 treatment and baPWV did not change
(Fig. 1). The patients were divided into categories of
baseline vitamin K insufficiency levels based on PIVKA-
2 or ucOC indicators. Regardless of the baseline level of
PIVKA-2 or ucOC, CAC similarly increased in each
group. To the contrary, baPWV was reduced signifi-
cantly by MK-4 supplementation in patients with a high
PIVKA-2 baseline (Fig. 2). However, the reduction was
not observed in patients with low PIVKA-2. A similar
pattern was observed with baseline ucOC levels, but it
was not statistically significant (Fig. 3).
Discussion
Despite high dose MK-4 supplementation, CAC in-
creased +14 % annually, but baPWV did not change
(−0.7 %). CAC similarly increased annually irrespective
of baseline vitamin K insufficiency. The MK-4
Table 2 Baseline data
Hemoglobin (g/dL) 13.8 ± 1.2
Albumin (g/dL) 4.2 ± 0.3
Triglyceride (mg/dL) 136 ± 82
alkaline phosphatase (IU/L) 223 ± 59
Blood urea nitrogen (mg/dL) 15 ± 3
Creatinine (mg/dL) 0.74 ± 0.24
ucOC (ng/ml) 3.7 ± 2.5
OC (ng/ml) 7.5 ± 2.7
ucOC/OC ratio 0.46 ± 0.18
PIVKA2 (mAU/mL) 19 ± 7
intact parathyroid horomone (pg/mL) 38.9 ± 22.0
Bone specific alkaline phosphatase (μg/l) 13.8 ± 6.5
NTX (nmol BCE/L) 16.9 ± 5.1
high sensitive C-reactive protein (mg/L) 929 ± 1132
Osteoprotegerin (ng/mL) 91.7 ± 30.8
oxidized low density lipoprotein (μg/dL) 104.9 ± 11.9
t-ucMGP (nmol/L) 2907 ± 1333
PK (ng/mL) 1.94 ± 1.38
MK-7 (ng/mL) 14.2 ± 11.9
MK-4 (ng/mL) 0.4 ± 2.0
ucOC uncarboxylated osteocalcin
OC osteocalcin
PIVKA2 protein induced by vitamin K absence or antagonist- 2
NTX collagen type 1 cross-linked N-telopeptide
t-ucMGP total circulating uncarboxylated matrix gla protein
PK philloquinone, MK menaquinone
Table 3 Change after 1 year MK-4 supplementation
CAC N Pre 1 year Difference %Difference Paired P value Baseline P value
Total 26 513 ± 773 588 ± 872 72 ± 143 +14 % 0.018
PIVKA2 ≦23 22 421 ± 543 481 ± 610 60 ± 132 +14 % 0.052 0.64
PIVKA2 >23 4 1010 ± 1558 1151 ± 1761 141 ± 204 +14 % 0.26
ucOC <4.5 19 348 ± 448 402 ± 515 55 ± 139 +16 % 0.11 0.38
ucOC ≧4.5 7 947 ± 1232 1064 ± 1387 117 ± 157 +12 % 0.09
PWV N Pre 1 year Difference Paired P value Baseline P value
Total 26 1834 ± 289 1821 ± 378 −12.7 ± 263 −0.7 % 0.811
PIVKA2 ≦23 22 1826 ± 280 1872 ± 379 47 ± 226 +2.6 % 0.34 0.79
PIVKA2 >23 4 1882 ± 379 1542 ± 248 −340 ± 164 −18 % 0.026
ucOC <4.5 19 1859 ± 293 1882 ± 410 22 ± 261 +1.2 % 0.71 0.26
ucOC ≧4.5 7 1766 ± 288 1659 ± 220 −107 ± 240 −6.1 % 0.28
Despite 1 year MK-4 supplementation, CAC increased +14 % annually. High PIVKA2 and high ucOC indicate vitamin K insufficiency at baseline. Those with high
PIVKA2 had significant reduction of PWV
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supplementation improved baPWV only in patients with
vitamin K insufficiency.
An annual increase of CAC was reported as 17 % in
the meta-analysis [20]. The mean annual CAC-
progression reported in the literature ranges from 24 to
51 % and has a large inter-individual variation depending
on many factors such as the baseline CAC-score,
medical history, medication-use, body-mass index, scan-
ner type and manufacturer [21]. This study showed 14 %
CAC increase annually, however it is unknown whether
MK-4 supplementation retarded progression because
this study lacks the control group. At the very least,
MK-4 did not stop CAC progression.
Fig. 1 a Paired profiles of coronary artery calcium scores before and
after MK-4 supplementation. b Paired profiles of pulse wave velocities
before and after MK-4 supplementation
Fig. 2 a Paired profiles of pulse wave velocities before and MK-4
supplementation in patients with PIVKA-2 < 23. b Those in patients
with PIVKA-2 > 23
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MK-7 supplementation significantly decreased
dephospho-uncarboxylated MGP dose-dependently [14].
MK-7 supplements may help postmenopausal women to
prevent bone loss [22]. Low-dose menaquinone-4 im-
proves gamma-carboxylation of osteocalcin in young
males [23]. Animal studies showed that high-dose MK-7
supplementation inhibits the development of cardiovascu-
lar calcification in rats [24]. Shea et al. reported that there
was no difference in CAC progression between PK supple-
mentation group and control group; the mean (±SEM)
changes in Agatston scores were 27 ± 6 and 37 ± 7, re-
spectively. A 270-day course of low-dose vitamin K2
(90 μg/day, MK-7) administration in patients with CKD
stages 3–5 may reduce the progression of atherosclerosis,
but does not significantly affect the progression of calcifi-
cation [25]. On the other hand, this study is as high as
high dose (45 mg/day, MK-4) The effective dose to protect
atherosclerosis or calcifications is unknown.
In terms of arterial stiffness, long-term use of MK-7
supplements improves arterial stiffness in healthy post-
menopausal women, especially in women having a high
arterial stiffness [15]. The results of this study were
similar to prior reports as have little preventive effects
on CAC. On the other hand, effects on arterial stiffness
were also observed in this study.
There are several limitations of this study. This study
was a small number, single center and a single arm
study. It is difficult to judge the effect of MK-4 because
of the lack of a control group.
In conclusion, despite MK-4 supplementation, CAC
progressed 14 % annually. The arterial stiffness was not
changed overall, but reduction was observed only in pa-
tients with baseline vitamin K insufficiency.
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